Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• CunninghamDAllumWHStenningSPMGIC Trial ParticipantsPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med20063551112016822992
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaAToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• OhtsuAShahMAVan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyJ Clin Oncol201129303968397621844504
   PubMed Web of Science ®Google Scholar
• FuchsCSTomasekJYongCJREGARD Trial InvestigatorsRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialLancet20143839911313924094768
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroe-sophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• EdgeSBComptonCCThe American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol20101761471147420180029
   PubMed Web of Science ®Google Scholar
• ChenAPSetserAAnadkatMJGrading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0J Am Acad Dermatol20126751025103922502948
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
   PubMed Web of Science ®Google Scholar
• ZhuHSunXZhouQChenLChenJWuPClinical study of Apatinib combined chemotherapy in the treatment of advanced gastric cancerChin J Surg Oncol201686394396
   Google Scholar
• GaoJHanTPiaoYApatinib combined tegafur in treatment for elderly or emaciated patients with advanced gastric cancerClin J Med Offic2017451912
   Google Scholar
• GaoFFangXThe short term efficacy of apatinib combined with CPT-11 and 5-FU in patients with advanced gastric cancerClin Album2016126624625
   Google Scholar
• WenFXiangYWangLClinical trial of apatinib tablets in the treatment of advanced gastric cancerClin Study2017337589591
   Google Scholar
• ChenZZhengQGuoBComparison of apatinib and S-1 in second line treatment of advanced gastric cancerChin J Clin Ratl Drug Use2017106A7980
   Google Scholar
• DingLXiaYWangWMengMYaoRBiJEfficacy and prognosis assessment of apatinib and S-1 in patients with advanced gastric cancerJ Anhui Tech Coll Health20171624849
   Google Scholar
• LangFZhaoYFanPClinical efficacy and safety of apatinib mesylatefor patients with advanced gastric cancerPract J Cancer2017326996998
   Google Scholar
• FanXLvHChenBClinical study of Apatinib combined with S-1 in the treatment of patients with advanced gastric cancer and review of literatureChin J Med Front2017926367
   Google Scholar
• WangDSongSWangKEfficacy assessment of apatinib combined with chemotherapy in patients with advanced gastric cancerWorld Latest Med Inf20161687130131
   Google Scholar
• WangPShangNLiuZDongXClinical research of apatinib combined with S-1 in patients with advanced gastric cancerJ Taishan Med Coll2016378919920
   Google Scholar
• XueDCuiLEfficacy assessment of apatinib in the treatment after failure of second line chemotherapy in patients with advanced gastric cancerContemp Med Symp20161422126127
   Google Scholar
• QinSLiJChinese specialist consensus on the treatment of gastric cancer with apatinibChin Clin Oncol2015209841847
   Google Scholar
• TakashimaABokuNKatoKSurvival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912Gastric Cancer201417352252824162387
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKVan CutsemERAINBOW Study GroupRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• ZhuAXParkJORyooBYRamucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialLancet Oncol201516785987026095784
   PubMed Web of Science ®Google Scholar
• TaberneroJYoshinoTCohnALRAISE Study InvestigatorsRamucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyLancet Oncol201516549950825877855
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHProteinuria in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysisChemotherapy2014605–632533326302785
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHRisk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysisExpert Opin Drug Saf201514101495150626313327
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHRisk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: a meta analysis and summary of other VEGF targeted agentsCrit Rev Oncol Hematol20161028910027129437
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOElHalawaniHRisk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysisFuture Oncol201511212949296126422782
   PubMed Web of Science ®Google Scholar